Osteoboost

Osteoboost is a wearable belt that delivers targeted vibration to the hips and lower spine. Worn for 30 minutes a day, it is designed to slow the loss of bone strength and bone density in postmenopausal women with osteopenia, which is low bone mass that has not reached osteoporosis.

In January 2024 it received FDA De Novo clearance as the first drug-free prescription treatment for osteopenia in postmenopausal women. You can wear it while you walk, cook, clean, do laundry, or get ready for the day.

It comes with a free iPhone app that tracks your sessions and reminds you to wear it, plus one year of Wellen, an exercise program for strength, balance, and posture.

• Postmenopausal women with osteopenia (a T-score between -1.0 and -2.5 at the spine or hip)
• Women who want a drug-free option
• Women who are losing bone but are not yet candidates for medication
• Women already working on strength and nutrition who want to do more

Who Should Not Use It

According to the manufacturer, Osteoboost should not be used if you have:

• A hip, knee, or ankle joint replacement
• A spinal fusion
• A herniated disc you are being treated for
• An active implant, such as a neurostimulator, in the spine, pelvis, or buttocks
• An allergy to neoprene

Osteoboost has not been studied in men and is not cleared for osteoporosis. If your fracture risk is high, medication is usually the more effective path, and we will walk you through your options.

Osteoboost was tested in a 12-month randomized, double-blind, sham-controlled trial at the University of Nebraska Medical Center, funded by the National Institutes of Health. 126 postmenopausal women with osteopenia wore either the real belt or an identical inactive (sham) belt.

• Across everyone in the study, the difference between the real and sham belts was not statistically significant.
• In women who wore it at least 3 times a week, the real belt significantly slowed the loss of spine bone strength and bone density, measured by CT-based bone modeling. This group is the source of the company's "85% less loss of spine bone density" figure.
• No device-related serious adverse events were reported.
• The trial measured bone strength and density, not fractures.

Some bone researchers have published concerns about how much these results show, and the study authors have published a response. Both are linked in the sources below.

Our take: Osteoboost is a reasonable, low-risk option for the right patient, and wearing it consistently is what matters. It is one part of a bone health plan, not a substitute for an evaluation or for medication when your fracture risk is high.

Preserve what you have, rebuild when needed. Osteoboost fits the preserve side: osteopenia, before bone loss is far along. When bone loss is further along or your fracture risk is high, today's medications can help restore bone, and we will tell you if that is the better path for you.

Either way, your plan also includes strength, balance, nutrition, and a repeat DXA to see how your bones are responding.

Osteoboost is self-pay. It is not yet covered by insurance or Medicare. As of October 2026, the launch price is $995 (list price $1,500). It is HSA/FSA eligible, and payments start as low as $63 a month through Affirm, with interest-free options available.

The price includes one year of the Wellen exercise program ($114 value), free shipping, a 30-day money-back guarantee, and a 1-year limited warranty.

Your visits with us are billed to your insurance as usual.

Osteoboost is one more tool we use within Connected Care, our long-term approach to maintaining your bone health between visits. Bone health is built over years, not in a single appointment.

The clearest lesson from the research is that Osteoboost works best when you actually wear it. Your care coordinator helps you track your progress, checks in, and helps you stay consistent, alongside the rest of your plan: strength, nutrition, medications when needed, and follow-up scans.

Connected Care is often covered by insurance. Standard copays or coinsurance may apply, and we check your benefits before you enroll.

Learn About Connected Care →

In its 12-month trial, women who wore it at least 3 times a week lost significantly less spine bone strength and density than women wearing an inactive belt. Across all participants, the difference was not statistically significant, and the trial did not measure fractures. Consistent use matters most.

Not yet. Osteoboost is self-pay. It is HSA/FSA eligible, with payments as low as $63 a month. Your visits with us are billed to your insurance as usual.

As of October 2026, the launch price is $995 (list price $1,500), or as low as $63 a month through Affirm, including one year of the Wellen exercise program, free shipping, and a 30-day money-back guarantee. Check osteoboost.com for current pricing.

According to the manufacturer: people with a hip, knee, or ankle joint replacement, a spinal fusion, a herniated disc being treated, an active implant in the spine, pelvis, or buttocks, or a neoprene allergy.

Osteoboost has not been studied in men and is cleared for postmenopausal women. Talk with your provider about the options that fit you.

Osteoboost is cleared for osteopenia, not osteoporosis. With osteoporosis or a high fracture risk, medication is usually the more effective path. We will review your options with you.

It has not been studied in combination with osteoporosis medications. Your provider can talk through whether combining them makes sense for you.

The manufacturer lists possible back, leg, or pelvic pain, skin irritation, and bruising, and temporary effects such as dizziness, headache, or stomach upset. Stop using it and contact us if you have pain or bruising.

You can. What we add is a full bone health evaluation: confirming your diagnosis, looking for other causes of bone loss, deciding whether Osteoboost or medication fits your fracture risk, and following up to make sure it is working.

Yes, in the states we serve. The device ships to your home, and we can help you set it up by video.